Clinical Trial

Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
While Carbetocin is effective in reducing PPH, the combination of oxytocin, Tranexamic acid, and Ergot derivatives may offer additional benefits in high-risk populations. We hypothesize that the combination regimen will reduce PPH incidence and severity compared to Carbetocin alone and may be more cost effective
Trial Details
NCT Number NCT07318467
Lead Sponsor Cairo University
Conditions Post Partum Hemorrhage
Enrollment 80 participants
Start Date 2026-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-06